Q-omics provides the consensus-scored RPL37A profile across patient tissues and cancer cell-line models. RPL37A expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPL37A is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, RPL37A protein abundance shows 23,033 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight ACC, KIRC, and PDAC as cancer lineages where RPL37A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL37A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL37A survival associations across molecular data types. RPL37A RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL37A RNA expression–survival associations across cancer types. High RPL37A expression shows unfavorable associations in ACC, KIRP, LIHC and SKCM, but favorable associations in UVM and LGG. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RPL37A RNA expression.
This table summarizes RPL37A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RPL37A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL37A shows lower tumor expression in BRCA and higher tumor expression in KIRC, COAD, LIHC, KIRP and CHOL. The KIRC box plot shows higher RPL37A RNA expression in tumor versus normal tissue (log2 FC = +0.968, t-test p < 0.001).
This table shows molecular features associated with RPL37A in patient tissues and cancer cell lines. In patient samples, RPL37A shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, RPL37A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
